Quick Answer
Allogene Therapeutics, Inc. reported Shares Outstanding of 229.41 million shares for fiscal year 2025.
Allogene Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 229.41M | +8.1% |
| 2024 | 212.21M | +25.8% |
| 2023 | 168.64M | +0.3% |
| 2023 | 168.18M | +0.6% |
| 2023 | 167.13M | +14.7% |
| 2023 | 145.74M | +0.9% |
| 2022 | 144.44M | +0.3% |
| 2022 | 144.03M | +0.2% |
| 2022 | 143.72M | +0.1% |
| 2022 | 143.57M | +0.7% |
| 2021 | 142.62M | +1.5% |
| 2020 | 140.47M | +13.0% |
| 2019 | 124.27M | +2.3% |
| 2018 | 121.48M | +362.8% |
| 2017 | 26.25M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 223.16M | +6.5% | +1.4% |
| June 30, 2025 | 220.13M | +5.3% | +0.7% |
| March 31, 2025 | 218.60M | +28.2% | +3.0% |
| December 31, 2024 | 212.21M | +25.8% | +1.3% |
| September 30, 2024 | 209.50M | +24.6% | +0.2% |
| June 30, 2024 | 209.05M | +25.1% | +22.6% |
| March 31, 2024 | 170.45M | +17.0% | +1.1% |
| December 31, 2023 | 168.64M | +16.8% | +0.3% |
- Allogene Therapeutics, Inc. showed an increase of +8.1% in Shares Outstanding compared to the prior fiscal year.
- Over the 2017–2025 period, Allogene Therapeutics, Inc.’s shares outstanding has grown by 774.0% (from 26.25 million shares to 229.41 million shares).
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: